This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Li, X., Song, W., Shao, C., Shi, Y. & Han, W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol. Immunol. 16, 28–39 (2019).
Wei, J. et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol. Immunol. 18, 792–804 (2021).
Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).
Lv, M. et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 30, 966–979 (2020).
Woo, S. R., Corrales, L. & Gajewski, T. F. Innate immune recognition of cancer. Annu Rev. Immunol. 33, 445–474 (2015).
Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568–586 (2019).
Fang, F., Xiao, W. & Tian, Z. NK cell-based immunotherapy for cancer. Semin Immunol. 31, 37–54 (2017).
Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Larkin, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397–402 (2017).
Acknowledgements
This work was supported by funds from the National Natural Science Foundation of China (Nos. 31991171, 81830002, and 31870873 to W.D.H.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, X., Dai, H., Wang, H. et al. Exploring innate immunity in cancer immunotherapy: opportunities and challenges. Cell Mol Immunol 18, 1607–1609 (2021). https://doi.org/10.1038/s41423-021-00679-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-021-00679-8
This article is cited by
-
Biomaterials as Antigen Delivery Carrier for Cancer Immunotherapy
Macromolecular Research (2021)